Shinshin Pharmaceutical Develops Universal Arthritis Treatment with Soluble Microneedles..."Diversifying Pharmaceutical Portfolio"

Transdermal drug delivery platform company Shinshin Pharmaceutical announced on the 17th that it has begun developing a new microneedle treatment for arthritis.

The microneedle drug currently under development can be applied to various types of arthritis, including osteoarthritis. By using a microneedle formulation, it directly penetrates the stratum corneum, minimizing lag time and rapidly reducing pain caused by arthritis compared to existing treatments. In addition, it enhances drug delivery volume, maximizing anti-inflammatory effects.

Shinshin Pharmaceutical plans to develop an arthritis treatment using a dissolvable microneedle formulation. The company intends to develop the treatment in accordance with the dissolvable microneedle drug guidelines established by the Ministry of Food and Drug Safety (MFDS). Since pilot product manufacturing process settings and various internal evaluations are already underway in the existing microneedle drug development process, the company explained that rapid commercialization is expected.

A Shinshin Pharmaceutical official stated, “Based on the proprietary technology and know-how secured during the microneedle drug development process, we decided to diversify our portfolio,” adding, “We will develop new treatments applicable to various arthritis diseases such as trigger finger and muscle pain, in addition to osteoarthritis, to maximize marketability.”

He continued, “The new treatment will be developed to act on localized areas to enhance efficacy, and synergy with the dissolvable microneedle drugs currently under development is expected,” adding, “Furthermore, we will develop microneedle drugs targeting various indications to advance related technologies and establish a foundation for entering the global market.”

Shinshin Pharmaceutical is developing the country’s first microneedle drug with the goal of applying for MFDS microneedle drug approval within this year.

This content was produced with the assistance of AI translation services.